Time to Next Treatment Slightly Higher With Elacestrant in HR+/HER2-, ESR1-Mutant Breast Cancer
Elacestrant (Orserdu) demonstrated an overall in-range or slightly higher time to treatment discontinuation and time to the next treatment compared with progression-free survival (PFS) observed in patients from the phase 3 EMERALD trial (NCT03778931) with …